Skip to main content

Table 2 Characteristics of included studies

From: Dzherelo (Immunoxel) as adjunctive therapy to standard antituberculosis treatment in patients with pulmonary tuberculosis: a systematic review and meta-analysis of clinical trials

Trials Country Study design Number of participants Intervention Comparator Ref
Arjanova et al. Ukraine Open-label trial 40 TB/HIV coinfected patients Immunoxel with ATT ATT alone [15]
Arjonova et al. Ukraine Open-label trail 40 TB/HIV coinfected patients Immunoxel with ATT ATT alone [6]
Batbold et al. Ukraine and Mongolia Double-blinded placebo controlled RCT 269 participants Immunoxel with ATT ATT with placebo [5]
Efremenko et al. Ukraine Unblinded RCT 69 patients, 76.8% with TB and 23.2% with TB/HIV co-infection Various Immunoxel formulations: sugar dragees, sugar-coated pills, gelatin pastilles and dried honey lozenges Sugar-coated pills without Immunoxel [7]
Zaitzeva et al. Ukraine Non-randomised controlled trial 75 newly PTB patients to assess the adjunct effect of Dzherelo on clinical outcomes and biochemical and blood parameters in patients with cavitary and infiltrating PTB Immunoxel with ATT ATT only [8]
Zaitzeva et al. Ukraine Non-randomised controlled trial 66 patients of which 48 had MDR-TB Immunoxel with ATT ATT alone [16]
  1. ATT antituberculosis therapy, RCT randomised controlled trial
Back to article page

Systematic Reviews

ISSN: 2046-4053